A machine learning approach to stratify patients with hypermobile Ehlers‐Danlos syndrome/hypermobility spectrum disorders according to disorders of gut brain interaction, comorbidities and quality of life
Neurogastroenterology & Motility · 2025-01 · 37 (1)
DOI: 10.1111/nmo.14957 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 14.11.2024. Verfasst von Anisa Choudhary und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Wingate Institute of Neurogastroenterology, Barts and The London School of Medicine a…. Hauptthemen laut MEDLINE: Quality of Life, Ehlers-Danlos Syndrome, Machine Learning, Comorbidity. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
A high prevalence of disorders of gut‐brain interaction (DGBI) exist in patients with hypermobile Ehlers‐Danlos Syndrome (hEDS) and hypermobility spectrum disorders (HSD). However, it is unknown if clusters of hEDS/HSD patients exist which overlap with different DGBIs and whether this overlap influences presence of comorbidities and quality of life. We aimed to study these knowledge gaps.
Methods
A prospectively collected hEDS/HSD cohort of 1044 individuals were studied. We undertook Uniform Manifold Approximation and Projection‐enabled (UMAP) dimension reduction to create a representation of nonlinear interactions between hEDS/HSD and DGBIs, from which individuals were stratified into clusters. Somatization, Postural Tachycardia Syndrome (PoTS), autonomic symptoms, psychological factors and quality of life were statistically compared between clusters. Key Results The mean age of patients was 40 ± 13.2 years; 87.8% were female. Patients segregated into three clusters: Cluster 0 ( n = 466): hEDS/HSD+ functional foregut disorders (FFD) + irritable bowel syndrome (IBS); Cluster 1 ( n = 180): hEDS/HSD+ IBS and Cluster 2 ( n = 337): hEDS/HSD alone. In cluster 0, we demonstrated increased somatization ( p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Wingate Institute of Neurogastroenterology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- High Dimensional Neurology Group, UCL Queen Square Institute of Neurology, University College London, London, UK.
- Centre for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Academic Department of Gastroenterology, Sheffield Teaching Hospitals and University of Sheffield, Sheffield, UK.
ORCID-Profile: Anisa Choudhary, James K Ruffle, Imran Aziz
Zitieren
APA
Choudhary, A., Fikree, A., Ruffle, J. K., Takahashi, K., Palsson, O. S., Aziz, I., & Aziz, Q. (2025). A machine learning approach to stratify patients with hypermobile Ehlers‐Danlos syndrome/hypermobility spectrum disorders according to disorders of gut brain interaction, comorbidities and quality of life. Neurogastroenterology & Motility, 37(1). https://doi.org/10.1111/nmo.14957
Vancouver
Choudhary A, Fikree A, Ruffle JK, Takahashi K, Palsson OS, Aziz I, et al. A machine learning approach to stratify patients with hypermobile Ehlers‐Danlos syndrome/hypermobility spectrum disorders according to disorders of gut brain interaction, comorbidities and quality of life. Neurogastroenterology & Motility. 2025;37(1). doi:10.1111/nmo.14957
BibTeX
@article{Choudhary2025,
author = {Choudhary, Anisa and Fikree, Asma and Ruffle, James K and Takahashi, Kazuya and Palsson, Olafur S and Aziz, Imran and Aziz, Qasim},
title = {A machine learning approach to stratify patients with hypermobile Ehlers‐Danlos syndrome/hypermobility spectrum disorders according to disorders of gut brain interaction, comorbidities and quality of life},
journal = {Neurogastroenterology & Motility},
year = {2025},
volume = {37},
number = {1},
doi = {10.1111/nmo.14957}
}
EUVIMED